Current therapeutic approaches for FRDA, including HDAC inhibitors and gene replacement therapy, are under development, with promising results reported in preclinical models, but their efficacy in rescuing FRDA phenotypes remains to be fully determined. The gene discussed is HDAC9; the disease is Friedreich ataxia.